Danaher Co. (NYSE:DHR) Shares Sold by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. lessened its holdings in shares of Danaher Co. (NYSE:DHRFree Report) by 27.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 44,986 shares of the conglomerate’s stock after selling 16,854 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Danaher were worth $10,407,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Norges Bank bought a new stake in shares of Danaher in the fourth quarter worth $1,752,382,000. Wellington Management Group LLP raised its stake in shares of Danaher by 18.6% in the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after purchasing an additional 3,905,449 shares in the last quarter. Allen Investment Management LLC lifted its position in shares of Danaher by 1,440.7% during the third quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock worth $273,009,000 after purchasing an additional 1,028,976 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC acquired a new position in Danaher in the third quarter worth about $178,850,000. Finally, Alecta Tjanstepension Omsesidigt bought a new stake in Danaher in the fourth quarter valued at about $161,994,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of DHR traded down $4.81 during trading hours on Tuesday, reaching $257.97. 1,520,347 shares of the company’s stock traded hands, compared to its average volume of 2,682,021. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $268.98. The business’s fifty day simple moving average is $250.19 and its two-hundred day simple moving average is $239.72. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. The firm has a market capitalization of $191.08 billion, a price-to-earnings ratio of 44.58, a P/E/G ratio of 4.02 and a beta of 0.83.

Danaher (NYSE:DHRGet Free Report) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. Danaher’s revenue was down 2.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.36 EPS. Analysts predict that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date is Friday, June 28th. Danaher’s payout ratio is currently 18.31%.

Insider Transactions at Danaher

In other Danaher news, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CFO Matthew Mcgrew sold 46,377 shares of Danaher stock in a transaction on Friday, May 10th. The stock was sold at an average price of $253.05, for a total value of $11,735,699.85. Following the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $7,441,441.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 148,783 shares of company stock valued at $37,536,717. Corporate insiders own 10.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Bank of America increased their target price on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a report on Wednesday, April 24th. Raymond James boosted their target price on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Royal Bank of Canada raised their price target on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Finally, Robert W. Baird raised their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average target price of $267.31.

Get Our Latest Analysis on DHR

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Further Reading

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.